Research digest — AEDG pineal tetrapeptide
Epitalon is the synthetic pineal tetrapeptide claimed to switch telomerase back on — here is what the research actually shows.
A broadsheet of the published record: the telomere findings, the lifespan studies, the single-laboratory provenance, and the telomerase-and-cancer question, with every claim study-attributed and cited.
The short version
Epitalon is a synthetic peptide — a tiny chain of just four amino acids (alanine, glutamate, aspartate, glycine, written AEDG). It was built to copy the active part of epithalamin, a substance taken from the pineal gland (a small organ in the brain that makes melatonin, the hormone that helps set your sleep clock). Researchers study Epitalon mainly for two reasons: a claim that it switches on telomerase, an enzyme that rebuilds the protective caps on the ends of your chromosomes, and a claim that it helps the body's day-night rhythm. Most of these findings come from cells in dishes and from mice and rats, and almost all of them come from one Russian research group. Epitalon is investigational. It is not approved as a medicine and it is not a dietary supplement. The headline anti-aging promises are not proven in careful human trials, and what people report — including the downsides — is on the effects page.
What the Epitalon literature has demonstrated
Added to telomerase-negative human fetal cells in culture, Epitalon switched on the catalytic telomerase subunit hTERT (the protein engine of the telomere-rebuilding enzyme), restored telomerase activity, and lengthened telomeres (the protective DNA caps that shorten each time a cell divides) [1]. In female SHR mice given 1.0 ug each, five days a month, maximum lifespan rose 12.3% and leukemia fell six-fold, with total tumor incidence unchanged [3]. In a 2025 review, Epitalon is described as a geroprotective AEDG tetrapeptide acting through melatonin synthesis, immune signaling, and telomerase — while the same review flags that the peptide's basic physical and structural characterization remains limited [4]. These are real, published results. They are also, in the main, results from cells and rodents, produced largely by a single laboratory. That distinction is the spine of this site, and we keep it visible: the Epitalon research page sorts the findings by the species and model they came from.
The provenance caveat, stated plainly
Almost the entire Epitalon evidence base — the human-cell telomerase result, the lifespan and cancer-model rodent work, and the often-quoted six-to-eight-year human mortality cohort — originates from one research lineage: Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [1][2][3]. Independent, non-Russian replication of the core telomere claim was sparse until 2024-2025 [5]. The human data are observational and open-label, never randomized or placebo-controlled to FDA or EMA standards [2]. None of this makes the findings false. It does mean the headline claims should be read as claims and single-group findings, not as established human fact.
Epitalon is not epithalamin, and it is not a supplement
Two confusions follow Epitalon everywhere. The first is with epithalamin, the polypeptide extract of the bovine pineal gland that Epitalon was modeled on; epithalamin is the parent preparation, Epitalon is the synthetic four-residue sequence derived from it, and the two are chemically and legally distinct [13]. The second is the word "store" or "supplement": Epitalon is neither an approved drug nor a dietary supplement, and it has never cleared the safety and purity review that regulated medicines undergo [4]. The spelling varies too — "Epithalon" and "Epithalone" are alternate forms of the same synthetic peptide; this site uses Epitalon throughout. The telomerase claim itself is double-edged, and we treat it carefully on the dedicated epitalon telomerase page.